Patrick Higgins, DO
Pulmonary Disease · Memphis, TNNPI 1235472507
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,943 of the $3,375 with a category attached, or 87.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in TN, where the typical reported total is $3,628.
Across 151 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$579
- GSK$563
- AstraZeneca$546
- Actelion Pharmaceuticals US, Inc.$479
- Boehringer Ingelheim$476
- United Therapeutics Corporation$158
- plus $573 from 15 others
Across 3 payments — averaging $15,067 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$44K
- AbbVie$800
What the payments were for
- Travel & lodging$43213%
- Food & beverage$2,94387%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $579 |
| GSK | 44 | $563 |
| AstraZeneca | 22 | $546 |
| Actelion Pharmaceuticals US, Inc. | 31 | $479 |
| Boehringer Ingelheim | 14 | $476 |
| United Therapeutics Corporation | 6 | $158 |
| Harmony Biosciences LLC | 4 | $107 |
| Insmed, Inc. | 3 | $69 |
| Sanofi | 3 | $68 |
| Verona Pharma, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Merck | 2 | $42 |
| Amgen | 2 | $32 |
| Electromed, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Novartis | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Viatris Specialty LLC | 1 | $14 |
| Inogen, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$302
- OFEV$104
How this compares
$3,375 in reported general payments places this provider in the 45th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 13 | $199,129 |
| OfevNintedanib Esylate | 12 | $150,496 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $105,823 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $29,561 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $27,215 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $24,786 |
| Qvar RedihalerBeclomethasone Dipropionate | 26 | $7,350 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 225 | $5,383 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,748 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 16 | $1,419 |
| Budesonide | 11 | $1,249 |
| Ventolin HfaAlbuterol Sulfate | 14 | $1,100 |
| Azithromycin | 88 | $798 |
| Mycophenolate Mofetil | 12 | $786 |
| Montelukast Sodium | 60 | $688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $69 | $199,12913 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $563 | $163,918238 claims |
| Boehringer IngelheimOfev | $476 | $150,49612 claims |
| AstraZenecaBreztri Aerosphere | $546 | $27,21539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Memphis
- Andrew HoltMemphis$69K
- Dipen KadariaMemphis$31K
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.